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Metal debris-related local reaction (adverse reaction to metal 
debris, ARMD) is a well-known complication of large-
diameter head metal-on-metal total hip replacement (MoM 
THR). More than 1 million MoM THRs were performed 
before widespread concerns about ARMD were raised (Lom-
bardi et al. 2012). The Australian Orthopaedic Association’s 
National Joint Replacement Registry (AOANJRR) was the 
first to report early failures of MoM THR (AOANJRR 2008). 
Despite the AOANJRR’s report, it took approximately 4 years 
for the European orthopedic community to adequately react to 
the issue (MHRA 2012). In Finland, the Finnish Arthroplasty 
Society recommended, in 2012, not to continue implantation 
of MoM THRs (Finnish Arthroplasty Society 2015).
ARMD is the most frequent cause of revision surgery among 
patients with large-diameter head MoM THR (Finnish Arthro-
plasty Register n.d.). Despite the implantations of MoM THRs 
having ceased, there are a large number of patients with MoM 
THR still in situ and these patients require regular follow-
up. Earlier studies have shown the relationship between high 
whole blood (WB) metal ion levels and failure of the MoM 
THR (Hart et al. 2014). Therefore, WB metal ion assessments 
have been used to detect ARMD, first to predict the failure of 
the implant and second to evaluate patients’ metal ion burden 
(Hannemann et al. 2013, Finnish Arthroplasty Society 2014).
It is recommended that patients with large-diameter head 
MoM THR should be regularly monitored with clinical exam-
ination, and when necessary with metal ion measurements 
and MARS-MRI (magnetic artifact reduction sequence-MRI) 
(Medicines and Healthcare products Regulatory Agency 2012, 
Background and purpose — Whole blood (WB) cobalt 
(Co) and chromium (Cr) ion levels have a major role in the 
follow-up of metal-on-metal total hip replacement (MoM 
THR). We investigated, first, if there was a change in WB 
Co or Cr levels over repeated measurements in patients with 
ReCap-M2A-Magnum THR, and, second, determined how 
many patients had WB Co or Cr levels that exceeded the safe 
upper limits (SUL) in the repeated whole blood metal ion 
assessment.
Patients and methods — A Recap-M2A-Magnum THR 
was used in 1,329 operations (1,188 patients) at our institu-
tion between 2005 and 2012. We identified all patients (n 
= 319) with unilateral ReCap-M2A-Magnum implants who 
had undergone at least 2 repeated metal ion measurements 
with the first blood sample taken mean 5.5 years (1.8–9.3) 
after surgery and the second taken mean 2 years (0.5–3) after 
the first.
Results — The median WB Co and Cr ion levels 
decreased in repeated measurements from 1.40 (0.40–63) 
ppb to 1.10 (0.20–68) ppb and from 1.60 (0.60–13.0) ppb to 
1.10 (0.30–19.0) ppb, respectively. 7% of the Co ion values 
exceeded SUL at the initial measurement, and 7% at the con-
trol measurement. The proportion of Cr ion values exceeding 
the safe upper limit (SUL) decreased during the measure-
ment interval from 5% to 4%.
Interpretation — Repeated metal ion measurements in 
unilateral ReCap-M2A-Magnum patients in a mean 2-year 
time interval did not show any increase. Long-term ion levels 
are, however, not yet known.
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Health Canada 2012, European Federation of National Asso-
ciations of Orthopaedics and Traumatology [Effort] 2012). 
However, it is unclear for how long and how often (interval) 
patients with a large-diameter head MoM THR should be 
screened. There are reports of repeated metal ion measure-
ments in a few MoM implants (van Der Straeten et al. 2013b, 
Reito et al. 2014), which have shown that it is useful to perform 
regular metal ion measurements. The tribology and failure rate 
of different designs of MoM THR prosthesis varies (AOAN-
JRR 2016). Therefore, studies with different implant designs 
are needed. As far as we know, there are no study reports on 
repeated whole blood metal ion measurements after implanta-
tion of the large-diameter head ReCap-M2A-Magnum THR.
The primary aims of our study were therefore to investigate:
1) if there is a substantial change in whole blood Co or Cr 
levels in repeated measurements performed a mean 24 
months (7 to 36) after the initial measurement in patients 
operated on with ReCap-M2A-Magnum THR; and
2) what proportion of patients with unilateral ReCap-M2A-
Magnum THR have whole blood Co or Cr levels exceed-
ing the safe upper limits in a mean 2-year time interval 
in the repeated measurements (chromium (Cr) 4.6 ppb, 
cobalt (Co) 4.0 ppb) (van der Straeten et al. 2013a).
Patients and methods
We established a screening program at our institution for 
MoM THR to identify patients with ARMD. The screening 
was done according to the follow-up protocol recommended 
by the Finnish Arthroplasty Society (2014). The screening 
included an Oxford Hip Score (OHS) questionnaire, antero-
posterior and lateral radiographs of the hip, and whole blood 
(WB) Cr and Co ion concentration measurements. Patients 
with moderate or poor OHS score, and/or patients with WB 
Cr or Co concentration > 5 ppb were referred for MRI using 
magnetic artifact reduction sequence (MARS). These patients 
were also clinically examined by a senior orthopedic surgeon 
at our outpatient clinic. Revision surgery for ARMD was con-
sidered if the patient had severe hip symptoms, such as pain, 
clicking, and swelling, and there was a clear pseudotumor on 
MRI. Revision surgery was also considered if an asymptom-
atic patient had very high WB metal ion levels (> 10 ppb) to 
avoid symptoms of Co poisoning (Rizzetti et al. 2009). All 
patients who were not revised were scheduled for annual or 
biennial repeat visits. Borderline cases were evaluated more 
frequently.
For this study, we identified all patients with unilateral 
ReCap-M2A-Magnum implants (1,047 patients). The stem 
used was the Biomet Bi-Metric (Biomet Orthopedics Inc, 
Warsaw, IN, USA). From the 264 patients without any ion 
measurements, 70 had been revised and 85 had died. Of 
these, 7 patients had been revised first and had died after-
wards (Figure 1). The rest of these patients with a unilateral 
ReCap-M2A-Magnum implant without any ion measurements 
were lost to follow-up. 783 patients made the first follow-up 
visit including WB metal ion measurements. From the 111 
patients without the second follow-up visit 12 patients had 
been revised, 3 had died, and 96 were lost to follow-up (Figure 
1). 336 patients (336 hips) had undergone 2 follow-up visits. 
9 patients had bilateral MoM hip devices and were excluded.
All participating patients had their blood samples taken from 
the antecubital vein using a 21-gauge BD Vacutainer Eclipse 
blood collection needle (Becton, Dickinson and Co, Franklin 
Lakes, NJ, USA). The first 10 mL tube of blood was used for 
analysis of standard laboratory tests such as C-reactive protein 
and erythrocyte sedimentation rate measurement. The second 
blood sample was taken in Vacuette NH trace elements tube 
(Greiner Bio-One GmbH, Kremsmünster, Austria) containing 
sodium heparin. Cobalt and chromium analyses from whole 
blood were performed using an accredited method with Induc-
tively Coupled Plasma Mass Spectrometry (ICP-MS, VITA 
Laboratory, Helsinki, Finland in collaboration with Medical 
Laboratory of Bremen, Germany). The detection limit for Cr 
was 0.2 ppb and for Co 0.2 ppb. The intra-assay variation for 
WB Cr and Co was 2.2% and 2.7% and inter-assay variation 
was 6.7% and 7.9%, respectively.
Statistics
319 patients met the criteria for this study with at least 2 
repeated metal ion measurements. The mean time elapsing 
from the first metal ion assessment (initial measurement) to 
the second (control measurement) was 2.0 years (SD 0.5, 
range 0.6–3.0). All unilateral ReCap-M2A-Magnum patients 
operated on at our institution are considered here as the con-
trol group, whereas those patients with 2 WB ion measure-
ments are referred to as the study group. A 2-sample t-test 
was used to test the difference in age, inclination angle, and 
femoral head diameter between the control and study groups. 
Sex distribution was compared using a chi-square test. Demo-
graphics were similar between the groups (Table 1).
Figure 1. Flow chart of the study.
Patients operated on with M2A-ReCap-Magnum THR
n = 1,188 patients with 1,329 hips
Patients with unilateral M2A-ReCap-Magnum THR
n = 1,047 
Patients included in the study
n = 319
Excluded
Bilateral M2A-ReCap-Magnum THR
n = 141 patients with 282 hips
Excluded (n = 728):
– revised, dead or lost to prior screening, 264
– attended only 1 follow-up visit, 447
– met exclusion criteria, 8
– other MoM implant in contralateral hip, 9
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The time elapsing from the index operation to the first 
metal ion measurement (initial) is referred to as follow-up 
time. Mean follow-up time between the index operation and 
the first metal ion measurement was 5.5 years (range 1.8 to 
9.3 years). Patients were divided into follow-up time inter-
val groups according to the time elapsing from the index 
operation to the first metal ion assessment. The time elapsing 
from the first metal ion measurement (initial) to the second 
measurement (control) in the same patient is referred to as 
the measurement interval. Thus total follow-up is defined 
as follow-up time plus measurement interval. The individ-
ual change in 2 consecutive metal ion measurements from 
the same patients was modelled using a random coefficient 
model. Log-transformed ion values were used in conditional 
models due to positively skewed distribution of ion levels. 
Results are expressed as geometric means for better interpret-
ability. SUL values for WB Co were 4.0 ppb and for WB Cr 
4.6 ppb as reported earlier (van der Straeten et al. 2013a). 
P-values lower than 0.05 in a 2-tailed test were considered 
statistically significant.
The change over a 2-year measurement interval was calcu-
lated and plotted as frequency distributions for both metal ions 
separately.
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Results
There was a statistically significant decrease in repeated WB 
Co and Cr values (Table 2). 
Geometric mean of WB Co and Cr levels did not change in 
the 2-year follow-up group. However, there were only 6 mea-
surements in the 2-year follow-up group. Geometric mean of 
WB Co and Cr values showed statistically significant decrease 
in the 3- to 6-year follow-up groups (Figure 2). 
Both WB Co and Cr concentrations remained within ±1 ppb 
of their initial value in most patients (86% for Co, 81% for 
Cr), with no trends towards increasing values (Figure 3).
Table 1. Comparison of demographic variables between the control 
group (= overall unilateral ReCap Magnum THR group, n = 1,047) 
and the study group (n = 319)
  Study group Control group p-value
Female patients (%) 59 55  0.2
Age (SD) 64 (9) 65 (10)  0.2
Median femoral head 
   diameter (SD), mm 49 (4) 49 (4)  0.4
Mean acetabular inclination (SD) 43 (7) 43 (8)  1
Table 2. Differences in WB CO and CR levels (ppb) 
 
  Initial Control  p-value
WB Co, n = 319
    median 1.4 (0.4–63) 1.1 (0.2–68)
    geometric mean 1.5 1.2 < 0.001
WB Cr, n = 317 
    median 1.6 (0.6–13) 1.1 (0.3–19)
    geometric mean 1.7 1.2  < 0.001
Figure 2. Geometric mean whole blood Co values (left) and Cr levels 
(right) divided across the follow-up time before initial measurement.
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Figure 3. Frequency distribution of change in whole blood Co levels 
(left) and Cr levels (right) compared with the initial measurement.
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6.6% of the Co ion measurements exceeded SUL at the ini-
tial measurement. The proportion increased slightly, being 7% 
at the control measurement. The proportion of SUL exceeding 
Cr ion levels decreased during the measurement interval from 
5% to 4%.
The Co and Cr levels decreased over time and stayed mostly 
below the SUL if the initial value was low. The exceptions 
were those with high values already at the start (Figure 4). 
The cobalt value increased from safe value to value above the 
safe limit in 8 patients, whereas the chromium value increased 
from safe value to value above the safe limit in 6 patients. 
Spaghetti plots for individual Co and Cr values at initial and 
control measurements are presented in Figure 5. Values are 
naturally log-transformed.
Discussion
We found that median or geometric mean WB Co and Cr 
levels in repeated metal ion measurements in unilateral 
ReCap-M2A-Magnum patients in a mean 2-year time interval 
did not show notable increase. Long-term ion levels are, how-
ever, not yet known. 
A limitation of our study was that the inclusion criterion 
used was arbitrary. We aimed to study changes in WB metal 
ion levels by repeated measurements, and the practical mea-
surement interval was 2 years. The time frame from the first 
measurement to the second was not constant, however, in our 
patients. Therefore, we were compelled to select a time range, 
and 7 to 36 months (mean 2 years) was deemed most suitable. 
It is possible that a longer time range between the measure-
ments such as 5 or 10 years might give different results. The 
long-term implant survivorship of the M2A-ReCap-Magnum 
THR, or long-term metal ion values of these patients, are not 
yet known. Further research is needed prior to determining 
whether a metal ion screening program of patients with this 
device should be ceased.
Another limitation of our study was also that most patients 
with severe hip symptoms and a clear pseudotumor in MRI 
had been revised and because of that did not undergo a 
second metal ion measurement. Most patients with very high 
WB ion levels initially had also been re-operated to avoid 
cobalt poisoning, and were not included. Therefore our study 
patients included mostly those with relatively low initial WB 
ion values. The progress of WB metal ion concentrations in 
patients with very high initial values is not known. Our find-
ings are not generalizable to other MoM devices.
From the 111 patients with only 1 follow-up visit, 12 had 
been revised and 3 had died. We acknowledge that there were 
many patients with only 1 metal ion measurement. However, 
this is about the same proportion as in the work of Reito et al. 
(2016b). Some of the patients were elderly with remarkable 
comorbidity and they may have chosen not to come for the 
repeated measurements even though the possibility was pro-
vided. In Finland the healthcare system refers patients mostly 
to the university hospital in their own district.
The group-level results may not be relevant from a single 
patient perspective. For the patient, it is more relevant to 
know if the metal level in his/her blood is high or not, what 
the expected change is in a repeated measurement, and which 
levels will raise concern. Even if only 5% of all patients have 
dangerously high blood levels it may be worth measuring the 
blood of all patients a second time or more. Therefore, we 
assessed our data additionally by modelling the individual 
change. However, also on individual level, the increase in ion 
levels on repeated measurements was rare.
The Medicines and Healthcare products Regulatory Agency 
(MHRA) and Health Canada have recommended a cutoff 
level of serum cobalt and chromium of 7 ppb (MHRA 2012, 
Health Canada 2012). MHRA even recommends repeated test-
ing within 3 months of abnormal results. European guidelines 
suggest that ion concentrations between 2 ppb and 7 ppb are 
of concern (EFORT 2012). The US Food and Drug Adminis-
tration in the USA and Therapeutic Goods Administration in 
Australia do not state any cut-off ion concentration thresholds 
(US FDA 2013, TGA 2012). According to Hart et al. (2011) a 
cut-off level of 7 ppb shows good specificity, but relatively low 
sensitivity. Lardanchet et al. (2012) suggested a cobalt cut-off 
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Figure 4. Changes in Co ion levels (left) and Cr ion levels (right) com-
pared with the initial measurement.
Figure 5. Spaghetti plots for individual Co and Cr values at initial and 
control measurements. Values are naturally log-transformed.
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level of 8 ppb. Van der Straeten et al. (2013a) defined SUL for 
unilateral hip resurfacing (HR) patients at Cr 4.6 ppb and Co 
4.0 ppb, and for bilateral HR patients at Cr 7.4 ppb and Co 5.0 
ppb. For our study purposes we decided to use the cut-off levels 
suggested by van der Straeten et al. (2013a). We do not think 
using other cutoff levels as SUL would change our message.
Of all MoM devices, metal ion levels of ASR (DePuy, 
Warsaw, IN, USA) THR and HR have been scrutinized most 
thoroughly. Reito and co-workers (2014) assessed 254 unilat-
eral patients, of whom 156 had received an ASR XL THR and 
98 patients an ASR HR (n = 254). The second blood sample 
was taken 8 to 16 months after the first. In the majority of HR 
patients both WB Cr and Co concentrations remained within 
±1 ppb in the second measurement and the majority of the 
values also remained below the SUL. However, in the THR 
group there was a significant increase in WB Co levels over 
the measurement interval and 32% of the patients exceeded 
the SUL during the measurement interval. They concluded 
that it is useful to perform regular WB metal ion measure-
ments in ASR XL THR patients, although not in ASR HR 
patients (Reito et al. 2014). In the current study we were not 
able to reproduce this finding in unilateral ReCap Magnum 
THR patients. The measurement interval of our study was 
even longer (mean 2 years) than in the study of Reito et al. 
(2014), and the decreasing tendency of WB ion levels was 
clear. The poorer performance of the ASR device may explain 
the difference in WB ion level development compared with 
the ReCap Magnum THR (Seppänen et al. 2018). Our data did 
not include any ReCap HR devices. 
In another study Reito et al. (2016b) showed that there is 
also a substantial increase in repeated Co and Cr level mea-
surements in patients with bilateral ASR THR, but not with 
HR patients. Additionally, 21% of THR patients had WB Co 
ion levels already exceeding the SUL in the first measurement 
(Reito et al. 2016b). Our current study did not include bilateral 
procedures, so these previous findings could not be verified 
using ReCap Magnum THRs. Further research is needed con-
cerning bilateral ReCap Magnum devices to assess WB ion 
level development tendency. 
Matharu et al. (2015) have previously raised concern 
regarding variable protocols worldwide in MoM THR screen-
ing. They have suggested further research to clarify blood 
metal ion thresholds, and whether thresholds differ between 
implants (Matharu et al. 2015). Our current results strengthen 
this impression. Implant-specific thresholds seem to be more 
effective to detect ARMD (Matharu et al. 2016a, 2016b, 2017). 
We might need specific thresholds for different implants to 
have better sensitivity and specificity in ARMD screening.
Our findings imply that patients with unilateral M2A-
ReCap-Magnum THR with WB metal ion levels below the 
SUL do not benefit from routine metal ion level screening, at 
least in a mean 2-year interval. We are aware that these find-
ings cannot be generalized to other LDH MoM THR brands. 
Due to the previous studies of repeated metal ion measure-
ments in ASR, the universal protocol may not be sufficient 
for all THR designs (Reito et al. 2016a). Implant-specific 
thresholds might be needed in the future to detect ARMD in 
different THR designs. Further, we do not know how the WB 
metal ion levels develop in the long term in unilateral ReCap-
Magnum patients. Wear and corrosion of the bearing surface 
and the trunnion may well increase in long-term follow-up. 
Further research is needed to assess the long-term benefits of 
WB ion measurements and to determine the specific thresh-
olds to detect ARMD in M2A-ReCap-Magnum THR patients. 
Further research is also needed to determine how frequently 
WB metal ion concentrations needs to be evaluated in these 
patients.
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